Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We are reiterating our Buy rating and C$3/share 12-month price target on Mydecine following the release of 3Q21 results. . . The highlight of the quarter was the announcement that Mydecine plans to continue clinical research that was initiated a number of years ago at Johns Hopkins University, under the leadership of Dr. Matthew Johnson, a world-renowned psychedelic drug researcher. In a small, preliminary, open-label pilot study (n=15), it was shown that 80% of the subjects achieved abstinence at six months following a 2-3 oral doses of psilocybin coupled with extensive cognitive behavioral therapy (‘CBT’). In a recent update, Dr. Johnson disclosed preliminary data from an ongoing 80-subject randomized trial. Fifty-nine percent of those treated with psilocybin and CBT were abstinent at 12 months vs. 27% with CBT treatment alone.”
To view the full report, visit https://ibn.fm/81dRX
About Mydecine Innovations Group Inc.
Mydecine Innovations is a biotechnology and digital technology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug-development infrastructure. Mydecine was founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovation in the mental health and therapeutic treatment environments. Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. The company’s business model combines clinical trials and data outcome, technology, and scientific and regulatory expertise with a focus on psychedelic therapy underpinned by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine Innovations Group aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way mental health disorders are viewed. Mydecine’s vision is to bridge the current gap between what the mental healthcare system currently provides with the needs of the patients. For more information, visit the company’s website at www.Mydecine.com.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at http://ibn.fm/MYCOF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork